Create Free Account

By creating account you will get access to hot stocks & personalised emails

Pharmaxis Ltd

Healthcare AU PXS

NoneAUD
-(-%)

Last update at 2024-03-12T06:45:07.451003Z

Day Range

--
LowHigh

52 Week Range

0.020.06
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap19.51M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-16.78000M
  • Revenue TTM11.89M
  • Revenue Per Share TTM0.02
  • Gross Profit TTM 7.77M
  • Diluted EPS TTM-0.02

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -11.36000M -1.93600M -2.97000M -13.94300M -20.05800M
Minority interest - - - - -
Net income -11.36000M -1.93600M -2.97000M -13.94300M -20.29600M
Selling general administrative 15.52M 14.08M 14.87M 14.46M 15.49M
Selling and marketing expenses 0.30M 0.76M 1.47M 1.35M 1.14M
Gross profit 3.06M -2.52700M 0.74M -0.77000M 5.68M
Reconciled depreciation 1.85M 3.24M 3.15M 3.24M 2.62M
Ebit -11.13700M -15.39200M -2.60100M -21.46700M -19.82000M
Ebitda -9.28900M -12.15400M 0.55M -18.23100M -17.20100M
Depreciation and amortization 1.85M 3.24M 3.15M 3.24M 2.62M
Non operating income net other - - - - -
Operating income -11.86400M -14.43800M -3.69600M -15.87900M -19.82000M
Other operating expenses 30.56M 17.42M 26.22M 29.08M 31.56M
Interest expense 0.22M 13.46M 0.37M 0.37M 0.24M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.39M 0.16M 0.57M 1.52M 1.58M
Net interest income -0.10600M 13.61M -0.31900M 2.52M 0.67M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 14.26M -6.23600M 18.36M -2.52400M 0.24M
Total revenue 5.76M 7.43M 6.68M 7.03M 5.68M
Total operating expenses 28.35M 30.19M 27.32M 28.49M 31.56M
Cost of revenue 2.71M 9.95M 5.93M 7.80M 1.37M
Total other income expense net 14.03M 7.22M 17.99M 5.00M -0.23800M
Discontinued operations - - - - -
Net income from continuing ops -11.36000M -1.93600M -2.97000M -13.94300M -20.05800M
Net income applicable to common shares -11.36000M -1.93000M -2.97000M -13.94300M -20.05800M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 24.03M 25.19M 33.59M 35.42M 52.67M
Intangible assets 0.68M 1.02M 1.11M 0.94M 0.76M
Earning assets - - - - -
Other current assets 0.33M 0.32M 0.22M 0.16M 0.14M
Total liab 14.47M 14.38M 30.75M 33.98M 37.85M
Total stockholder equity 9.56M 10.80M 2.85M 1.43M 14.81M
Deferred long term liab - - - - -
Other current liab 3.47M 0.26M 1.02M 0.48M 1.11M
Common stock 389.70M 380.44M 371.37M 367.30M 367.30M
Capital stock 389.70M 380.44M 371.37M 367.30M 367.30M
Retained earnings -404.45300M -393.09300M -391.15700M -388.18700M -374.24400M
Other liab 6.43M 8.63M 18.57M 20.84M 23.77M
Good will - - - - -
Other assets 2.82M 2.56M 0.94M 1.08M 1.07M
Cash 9.23M 8.94M 18.71M 14.76M 31.12M
Cash and equivalents 5.98M 2.50M 9.25M 2.70M 2.65M
Total current liabilities 8.03M 6.10M 7.89M 6.83M 8.11M
Current deferred revenue 0.94M 3.19M 3.60M 2.75M 3.60M
Net debt -7.18700M -4.64700M -12.39000M -6.61000M -23.95300M
Short term debt 2.04M 2.03M 2.03M 1.83M 1.20M
Short long term debt - - - - -
Short long term debt total 2.04M 4.29M 6.32M 8.15M 7.17M
Other stockholder equity 24.31M 23.46M 22.64M 22.32M 21.76M
Property plant equipment 1.84M 3.21M 6.23M 8.91M 10.26M
Total current assets 18.68M 19.23M 25.31M 24.49M 40.58M
Long term investments - - - - -
Net tangible assets 8.88M 10.80M 1.73M 0.49M 14.06M
Short term investments 2.77M 6.00M 8.53M 11.31M 28.33M
Net receivables 7.48M 7.64M 2.74M 6.94M 7.19M
Long term debt - - - - 7.17M
Inventory 1.64M 2.34M 3.64M 2.63M 2.12M
Accounts payable 1.58M 0.61M 1.24M 1.76M 2.20M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 24.31M 23.46M 22.64M 22.32M 21.76M
Additional paid in capital - - - - -
Common stock total equity - - - 367.30M 367.30M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -2.52500M -4.23600M -7.33900M -9.84700M 1.07M
Deferred long term asset charges - - - - -
Non current assets total 5.35M 5.95M 8.28M 10.92M 12.09M
Capital lease obligations 2.04M 4.29M 6.32M 8.15M 7.17M
Long term debt total 0.00000M 2.26M 4.29M 6.32M 5.97M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.13100M -0.30600M -0.64400M -0.57400M -0.98100M
Change to liabilities 1.08M -0.62500M -0.52000M -0.43700M 0.07M
Total cashflows from investing activities -0.13100M -0.13800M -0.64400M -0.57400M -0.98100M
Net borrowings -2.24700M -2.37900M -2.30500M -2.23200M -1.59300M
Total cash from financing activities 6.98M 6.63M 1.52M -2.50200M 20.83M
Change to operating activities -2.09600M -5.14100M 5.22M -0.32900M -6.02200M
Net income -11.36000M -1.93600M -2.97000M -13.94300M -20.29600M
Change in cash 0.29M -9.77500M 3.95M -16.36000M 0.05M
Begin period cash flow 8.94M 18.71M 14.76M 31.12M 31.07M
End period cash flow 9.23M 8.94M 18.71M 14.76M 31.12M
Total cash from operating activities -7.27700M -16.30300M 3.07M -13.28400M -19.79800M
Issuance of capital stock 10.00M 9.74M 4.37M - 24.00M
Depreciation 1.81M 3.12M 3.03M 3.12M 2.62M
Other cashflows from investing activities - -0.13800M -0.64400M -0.57400M -0.57400M
Dividends paid - - - - -
Change to inventory 0.70M 1.30M -1.00800M -0.51400M 0.28M
Change to account receivables 0.27M -1.41400M 0.29M -0.28800M 0.62M
Sale purchase of stock -0.74100M -0.66800M -0.30100M -0.30100M 24.00M
Other cashflows from financing activities -2.28000M -2.44100M -2.54500M -2.50200M -3.17000M
Change to netincome 2.29M -17.60400M -1.08800M -1.00900M 2.46M
Capital expenditures 0.14M 0.31M 0.65M 0.57M 0.98M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.96M -0.11300M -0.71900M -0.80200M 0.90M
Stock based compensation 0.82M 0.82M 0.32M 0.56M -
Other non cash items 2.27M -17.48800M 3.01M -2.46600M 17.44M
Free cash flow -7.41500M -16.61000M 2.42M -13.85800M -0.98100M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PXS
Pharmaxis Ltd		 - -% - - 20.45 1.64 1.81 1.76 -1.0933
AFP
AFT Pharmaceuticals Ltd		 -0.04 1.54% 2.55 25.90 19.08 1.39 3.57 1.61 13.92
LV1
Live Verdure Ltd		 0.02 2.56% 0.80 - - 68.21 49.49 66.86 -5.083
VLS
Vita Life Sciences Ltd		 - -% 1.78 11.12 - 1.34 2.16 0.99 5.71
SNT
Syntara Limited		 0.002 3.23% 0.06 - 20.45 15.25 19.66 6.32 -2.1607

Reports Covered

Stock Research & News

View All

Profile

Syntara Limited operates as a clinical stage drug development company that focuses on blood-related cancers. Its lead product candidate is PXS-5505, which is in phase 2 trial for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue leading to loss of red and white blood cells and platelets. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.

Pharmaxis Ltd

Pax World Funds Series Trust I

Key Executives

Name Title Year Born
Mr. Gary Jonathan Phillips BPharm, MBA CEO, MD & Director 1961
Mr. David Morris McGarvey BA, CA, CPA CFO & Company Sec. 1956
Dr. Wolfgang G. Jarolimek B.Sc. Ph.D., Ph.D. Head of Drug Discovery 1964
Ms. Kristen Morgan B.Sc., BSc, MMedSc, PGDipBusAdmin Head of Medical & Regulatory Affairs - Alliance Management 1972
Dr. Jana Baskar Chief Medical Officer NA
Mr. Cameron David Billingsley Gen. Counsel 1977
Dr. Dieter Hamprecht Head of Chemistry for Drug Discovery NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.